Antios Therapeutics Appoints Accomplished Economical Executive, Tamra J. Adams, as its initial Chief Fiscal Officer

ATLANTA, Feb. 17, 2021 (World NEWSWIRE) — Antios Therapeutics, Inc. (“Antios”) these days introduced the appointment of seasoned economic govt, Tamra J. Adams, as the Company’s main financial officer (CFO) successful March 1, 2021. Ms. Adams fills a newly designed government place at Antios as section of the Company’s swift development.

“We have just lately finished a Stage 1b scientific demo of our guide asset, ATI-2173, a probable backbone cure in a useful curative routine for persistent HBV an infection, and foresee presenting proof-of-concept data from the study in mid-2021,” explained Gregory Mayes, chief executive officer of Antios. “We also appear forward to aggressively going the plan into Section 2 which will begin subsequent thirty day period. For that rationale, including a senior fiscal govt professional with emerging advancement providers, together with in biopharmaceuticals, to the govt management group is a important action at this time. Tamra and I labored closely with each other at Interact Therapeutics for 3 years and I seem ahead to collaborating with her all over again as we keep on to speedily progress the growth of ATI-2173 and evolve as a business.”

Ms. Adams has a lot more than 25 years of expertise in accounting and monetary management. In advance of signing up for Antios, she started Accounting Principles, Inc., a agency that presented CFO, accounting, and money solutions to rising growth providers in the biopharmaceutical and details technologies industries, which includes Have interaction Therapeutics, a company that was marketed to UCB in 2020. Before that, Ms. Adams was a senior economic govt at Silverstorm Technologies, Inc., exactly where she was responsible for economical and human resources capabilities and participated in an acquisition of the organization by QLogic. Prior, she was the Controller of Starcite, Inc., an online enterprise, where by she was liable for money reporting, organization design growth and internal command units. Ms. Adams commenced her profession at Ernst & Youthful, LLP, as a Senior Auditor specializing in entrepreneurial services and afterwards at Goldman Sachs as a Senior Accounting Officer. Ms. Adams acquired her B.S. in Accounting at State College of New York, Albany and is a certified general public accountant in New York.

“I have used the greater part of my occupation taking care of the economic infrastructure for rising advancement organizations and working with Antios gives me the chance to continue on developing on that operate,” stated Ms. Adams. “The corporation is on a swift development trajectory and has the prospective to make a considerable contribution to public health. I appear forward to supporting create Antios into a major biopharmaceutical company with the relaxation of the crew.”

About ATI-2173
ATI-2173 is a novel, orally administered, liver-focused Lively Internet site Polymerase Inhibitor Nucleotide (ASPIN) molecule created to provide the 5’-monophosphate of clevudine to the liver. This L-nucleoside’s active 5’-triphosphate has distinctive antiviral homes as a non-competitive, non-chain terminating HBV polymerase inhibitor that distorts the lively website of HBV polymerase ensuing in potent HBV antiviral exercise and extended off-remedy suppression of HBV DNA. ATI-2173 targets the liver, delivering significant levels of the exceptional 5’- triphosphate although restricting systemic exposure to the guardian L-nucleoside. ATI-2173 has the potential to grow to be an integral section of a curative mix regimen for continual hepatitis B.

About Antios Therapeutics Inc.
Antios Therapeutics is a medical-phase biopharmaceutical company targeted on the development of modern therapies to deal with and heal viral disorders. Antios is at present acquiring ATI-2173, aiming to offer persistent hepatitis B contaminated people with a healing blend routine.

CONTACTS

Buyers:
Lee Roth
Burns McClellan
[email protected]
+1 (212) 300-8331

Media:
Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan
[email protected] / [email protected]
+1 (212) 300-8315 / +1 (212) 300-8364